��������

Sabzevari takes over the reins of the company from Randall Kirk, who was named executive chairman of the board of directors. She joined the company in 2017 and has served as president of the Precigen subsidiary since. As CEO, Sabzevari will be tasked with improving the lives of patients “with novel therapies that harness transformational approaches in gene and cell therapies, microbe-based biotherapeutics, and regenerative medicine.”